Literature DB >> 27501139

Hydroxyapatite (HA) microparticles labeled with (32)P - A promising option in the radiation synovectomy for inflamed joints.

A Rajeswari1, K V Vimalnath1, H D Sarma2, Priyalata Shetty1, Shahiralm Khan Mohammed1, Jitendra Nuwad3, Sudipta Chakraborty4, Ashutosh Dash1.   

Abstract

In the present article we describe a systematic approach pursued for the synthesis of (32)P-labeled hydroxyapatite (HA) microparticles (1-10µm size range) using no carrier added (NCA) (32)P produced in a nuclear reactor and animal evaluation of its utility as an expected viable radiopharmaceutical for the treatment of pain intensive arthrosis. NCA (32)P was produced via the (32)S(n,p)(32)P route in nuclear reactor with high radionuclidic purity (99.95±0.01%, n=5). Phosphorus-32-labeled hydroxyapatite microparticles (1-10µm size range) were synthesized with high radiochemical purity (99.0±0.3% n=12) under optimized conditions and the formulation showed excellent in vitro stability in saline as well as in rat serum. Intra-articular administration of the radiolabeled particles in the knee joints of normal Wistar rats showed near-complete retention of activity within the synovial cavity upto 1 month post-administration. The radiochemical formulation thus demonstrated promising features as a radiopharmaceutical for treatment of arthritis with excellent logistic advantage for shipment to sites distant from the production facility thanks to the suitable nuclear decay properties of (32)P.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arthritis; Hydroxyapatite (HA) microparticles; NCA (32)P; Radiation synovectomy; Radiolabeling

Mesh:

Substances:

Year:  2016        PMID: 27501139     DOI: 10.1016/j.apradiso.2016.07.022

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  1 in total

1.  Surface protolytic property characterization of hydroxyapatite and titanium dioxide nanoparticles.

Authors:  Ekaterina Kukleva; Petra Suchánková; Karel Štamberg; Martin Vlk; Miroslav Šlouf; Ján Kozempel
Journal:  RSC Adv       Date:  2019-07-15       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.